NCT06684795View on ClinicalTrials.gov

FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Low-grade GliomaMeningiomaGlioma
Interventions
DRUG

FG001 prior to surgery

Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.

Trial Locations (1)

2100

RECRUITING

Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER